18We assessed the virulence and anti-trypanosomal drug sensitivity patterns of Trypanosoma 19 brucei rhodesiense (Tbr) isolates in the Kenya Agricultural and Livestock Research 20 Organization-Biotechnology Research Institute (KALRO-BioRI) cryobank. Specifically, the 21 study focused on Tbr clones originally isolated from the western Kenya/eastern Uganda focus of 22 human African Trypanosomiasis (HAT). Twelve (12) Tbr clones were assessed for virulence 23 using groups(n=10) of Swiss White Mice monitored for 60 days post infection (dpi). Based on 24 survival time, four classes of virulence were identified: (a) very-acute: 0-15, (b) acute: 16-30, (c) 25 sub-acute: 31-45 and (d) chronic: 46-60 dpi. Other virulence biomarkers identified included: pre-26 patent period (pp), parasitaemia progression, packed cell volume (PCV) and body weight 2 27changes. The test Tbr clones together with KALRO-BioRi reference drug-resistant and drug 28 sensitive isolates were then tested for sensitivity to melarsoprol (mel B) pentamidine, diminazene 29 aceturate and suramin, using mice groups (n= 5) treated with single doses of each drug at 24 30 hours post infection. Our results showed that the clones were distributed among four classes of 31 virulence as follows: 3/12 (very-acute), 3/12 (acute), 2/12 (sub-acute) and 4/12 (chronic) isolates. 32 Differences in survivorship, parasitaemia progression and PCV were significant (P<0.001) and 33 correlated. The isolate considered to be drug resistant at KALRO-BioRI, KETRI 2538, was 34 confirmed to be resistant to melarsoprol, pentamidine and diminazene aceturate but it was not 35 resistant to suramin. At least 80% cure rates of all the test isolates was achieved with melarsoprol 36 (1mg/Kg and 20 mg/kg), pentamidine (5 and 20 mg/kg), diminazene aceturate (5 mg/kg) and 37 suramin (5 mg/kg) indicating that the isolates were not resistant to any of the drugs despite the 38 differences in virulence. This study provides evidence of variations in virulence of Tbr isolates 39 from a single HAT focus and confirms that these variations are not a significant determinant of 40 isolate sensitivity to anti-trypanosomal drugs. 41